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ABSTRACT
The world is facing an epidemic rise in diabetes mellitus (DM) incidence, which is challenging health
funders, health systems, clinicians, and patients to understand and respond to a flood of research and
knowledge. Evidence-based guidelines provide uniform management recommendations for “average”
patients that rarely take into account individual variation in susceptibility to DM, to its complications, and
responses to pharmacological and lifestyle interventions. Personalized medicine combines bioinformatics
with genomic, proteomic, metabolomic, pharmacogenomic (“omics”) and other new technologies to explore
pathophysiology and to characterize more precisely an individual’s risk for disease, as well as response to
interventions. In this review we will introduce readers to personalized medicine as applied to DM, in
particular the use of clinical, genetic, metabolic, and other markers of risk for DM and its chronic
microvascular and macrovascular complications, as well as insights into variations in response to and
tolerance of commonly used medications, dietary changes, and exercise. These advances in “omic”
information and techniques also provide clues to potential pathophysiological mechanisms underlying DM
and its complications.
Abbreviations: ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; DM, diabetes mellitus; DM2,
type 2 diabetes mellitus; GWAS, genome-wide association study; HbA1c, hemoglobin A1c; MODY, maturity-onset diabetes
of the young; SNP, single nucleotide polymorphism.
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INTRODUCTION
Recent decades have seen a dramatic worldwide
increase in the incidence and prevalence of diabetes
mellitus (DM), particularly of type 2 DM.1 The
potential impact of DM on health, health care costs,
productivity, and life expectancy in the upcoming
years will be enormous. Contemporaneously, there
has been substantial progress in a wide range of
treatments for DM and for its chronic complications,
leading to improved life expectancy.2,3 Expert bodies
now regularly publish “standards of care” and
recommendations addressing all aspects of DM
management.4–6 Such documents address the care
needs of the average or typical patient with DM,
based largely on the findings of studies advancing
our understanding of the pathophysiology of DM
and its complications, as well as randomized control
treatment trials. Optimal therapy of DM requires
potentially complex measures to control
hyperglycemia, prevent hypoglycemia, and to
address risk factors for a range of diabetic
complications. The caregiver has also to be aware of
the patient’s social, cultural, and eco-system
components (environmental components within the
closed community—like housing and neighborhood). Many patients are unable to reach treatment
goals due to the difficulty, complexity, and costs of
treatment.7 Recognizing the wide range of patients
with DM, recent guidelines now stress the need to
personalize DM management goals and treatments.8
In the face of the “diabetes tsunami”9 the gap
between knowledge derived from basic scientific and
clinical research, including newly recognized
molecular mechanisms and updated medical
management guidelines and their use at the bedside
or point of care by practitioners, is growing.
Developing strategies and tools to bridge this
knowledge and implementation gap is increasingly
urgent as medically relevant and novel scientific
discoveries can now be applied to assess risk factors
at the genomic level for chronic diseases like cancer
and DM, as well as the sensitivity to and efficacy of
drug therapy using tools like bioinformatics and
pharmacogenomics. These fields, together with the
evolving areas of genomics, proteomics, and
metabolomics, constitute the premise and promise
of personalized medicine.
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Evidence-based medicine seeks to narrow the
gap between clinical research and practice by
explicitly and systematically focusing the attention
of clinicians on the most up-to-date evidence from
epidemiologic and clinical trial studies. Specifically,
evidence-based medicine promotes the judicious use
of meta-analyses of randomized controlled trials and
other scientifically derived knowledge for clinical
decision-making. However, an inherent weakness of
the meta-analytical focus is that individuals vary
greatly in regard to their manifestations of disease,
symptoms, co-morbidities, genetic predisposition,
and variance in molecular sensitivity to drugs, which
cannot be reflected in guidelines derived from metaanalyses of the general patient population.
According to the US President’s Council of
Advisors on Science and Technology,10
personalized medicine refers to the tailoring
of medical treatment to the individual
characteristics of each patient; […] the ability
to classify individuals into subpopulations
that differ in their susceptibility to a
particular disease or their response to a
specific treatment. Preventive or therapeutic
interventions can then be concentrated on
those who will benefit, sparing expense and
side effects for those who will not.10
Given the large health and economic impact of
DM, there is understandable interest in using
personalized medicine strategies to identify those
individuals who are most at risk of developing DM
and its various complications, and who are most
likely to benefit from a specific management
strategy, in order to apply proven measures to delay
or prevent their progression to DM and its
subsequent complications.11,12 In this review we will
provide an introduction to the principal
personalized medicine tools and strategies, and
provide examples of how they may be applied to
diabetes, in particular to type 2 DM (DM2). This
includes enhanced prediction of the onset and
course of DM and its complications, treatment
planning (choice of treatment modality), treatment
prioritization and goal setting, and recognition of
potential pathophysiologic mechanisms of DM and
its complications.
2
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PERSONALIZED MEDICINE AND THE
NEW “OMICS”
Taking advantage of high-throughput technological
developments in the laboratory and advances in
data management capabilities, it is now possible to
acquire and analyze very large volumes of information from studies of genetic and metabolic markers
from great numbers of individuals. This has led to
the fields of genomics, proteomics, transcriptomics,
metabolomics, and pharmacogenomics (see Glossary for definitions). Analyses of large numbers of
variants from genome-wide association studies
(GWAS), or of large numbers of protein and other
metabolites in body fluids, from large cohorts that
may number in the tens of thousands generate
enormous amounts of data. The field of bioinformatics uses “big data” approaches to organize and
usefully analyze these data sets to recognize patterns
and associations that may have pathophysiologic,
diagnostic, prognostic, or therapeutic utility.
These tools of personalized medicine may be
used to predict risk for developing DM, as well as an
individual patient’s risk of developing one or all of
the complicating morbidities associated with DM,
such as retinopathy, neuropathy, nephropathy, or
large-vessel disease (macrovasculopathy). They also
have potential to guide treatment planning, in terms
of personalized goal setting, choice of treatments,
and treatment prioritization.
Genomics and Type 2 Diabetes Mellitus
Studies of the family medical history of those with
DM2 as well as observation of differential incidence
of DM in different ethnic groups have long pointed
to a significant inherited component to DM2 susceptibility. Nevertheless, the rapid rise in DM2
incidence in the last few decades suggests the
interaction of changes in environment and lifestyle
with genetic predisposition. The principle of
genome-wide association studies is to investigate
differences in the prevalence of genetic variations
(single nucleotide polymorphisms, SNPs) in DNA
samples from populations with and without the
condition of interest. Significant differences point to
possible etiological associations with the condition.
Recent expansion of genome-wide association
studies to include “environment-wide associations”
may help identify novel nutritional or other
environmental interactions that modulate genetic
predisposition to DM.13 After the successful cloning
of the human genome, initial enthusiasm about the
possibility of identifying the specific genetic basis
Rambam Maimonides Medical Journal

for DM2 has been followed by the realization that a
large number of genes contribute to DM2 susceptibility. These include CDKAL1, CDKN2A , and
CDKN2B that influence β-cell mass; MTNR1B,
TCF7L2, and KCNJ11 that influence β-cell function;
FTO that is associated with obesity; and IRS1 and
PPAR-γ that contribute to insulin resistance
independent of obesity.14 Furthermore, there may be
unique markers of genetic susceptibility to DM2 in
certain ethnic groups with a high incidence of
DM2,15,16 and interactions between individual
genetic variants may also influence DM risk. For
example, in a study of an Ashkenazi Jewish population, the presence of HNF4A or WFS1 SNPs was
each associated with modestly increased risk of DM,
while the presence of both increased that risk threefold.17 Unfortunately, although genome-wide association studies have already identified over 65 gene
variants related to DM2,18 predominantly involved
in β-cell function,19 collectively they explain only a
small portion (<10%) of DM2 heritability.20 Thus,
while family history of DM approximately doubles
the risk of developing DM, the genetic variants
associated with DM risk have only a small effect on
the ability to predict the future development of the
disease.21 It is very likely that epigenetic changes
contribute to familial clustering of risk for obesity
and DM,22 changes that by definition are not
detectable with genomic studies.
In contrast to DM2, a small number of monogenic defects have been recognized to cause the
uncommon autosomal dominantly inherited forms
of maturity-onset diabetes of the young (MODY).23
These defects disrupt β-cell function, and their
recognition and precise genetic diagnosis is clinically important in directing treatment towards more
effective and easier-to-use sulfonylurea drugs rather
than insulin. The most common form (MODY3)
results from a mutation of hepatocyte nuclear
factor-1α on chromosome 12.24 In MODY2, a defective glucokinase gene on chromosome 7P results in
disturbed β-cell sensing of glucose concentration.
Transcriptomics and Type 2 Diabetes
Mellitus
Sometimes referred to as gene expression profiling,
transcriptomics is the quantitative study of all genes
expressed in a given biological state25 and measures
all of the various RNA forms (messenger, ribosomal,
transfer, etc.) produced by DNA transcription in a
particular cell or tissue. MicroRNAs are small, noncoding RNAs that are involved in control of gene
3
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expression and play an important role in regulating
metabolic and cardiovascular processes.26 In
combination with metabolomics, transcriptomic
studies in animal models of DM have identified a
number of novel genetic and metabolic changes,
including differences in branched-chain amino
acids, nicotinamide metabolites and pantothenic
acid, that provide direction for additional studies of
diabetes pathophysiology.27
Proteomics and Type 2 Diabetes Mellitus
Techniques such as matrix-assisted laser
desorption/ionization,28 mass spectroscopy, and
electrospray ionization,29 alone or in combination,
are used to identify and quantify all of the large
number of protein products of a genome, in a
specific tissue or body fluid. Differences associated
with obesity, DM, or other disease states may
identify novel pathogenic mechanisms, prognostic
markers, or potential therapeutic targets. Study of
proteomics is complementary to genomics, as posttranslational modifications of proteins of potential
importance to understanding the pathophysiology of
DM and its complications in tissues such as adipose
tissue or skeletal muscle will not be detected by
genomic studies.30
Metabolomics and Type 2 Diabetes Mellitus
Metabolomics uses tools such as nuclear magnetic
resonance and mass spectroscopy to identify and
quantitate large numbers of small-molecule
products of metabolism. “Targeted” metabolomic
studies are limited to a certain category of metabolites of interest (e.g. amino acids). In the field of
DM, metabolomics has helped identify novel risk
factors for DM, which may be useful biomarkers for
early DM risk31,32 and may also serve as clues to
increase understanding of the complex pathophysiology of DM2. Analysis of many metabolites in
baseline samples from large prospective population
studies, such as the Framingham Heart Study, has
identified strong independent predictive relationships between levels of branched-chain and
aromatic amino acids (isoleucine, leucine, valine,
tyrosine, and phenylalanine) and risk of DM
incidence over 12 years.31 Further studies in this
population identified a novel metabolite (2aminoadipic acid) which is independently predictive
of DM risk, pointing to a potential different
pathophysiologic pathway underlying DM.33 The
field of “lipidomics” employs the analytic technology
and large data set approach of metabolomics to
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study variations in lipid structures. Using the same
Framingham Heart Study population, Rhee et al.
found that shorter triacylglycerol fatty acid chain
length and lower double-bond content reflect insulin
resistance and serve as an independent marker of
DM risk.34 The potential role of metabolomic studies
in DM research and practice has recently been
reviewed.35,36
Pharmacogenomics and Type 2 Diabetes
Mellitus
Pharmacogenomics studies the effect of genetic
variations on drug kinetics or action. Genetically
determined differences in absorption or metabolism
of an agent, or variation in tissue responsiveness,
may increase or decrease the effectiveness or side
effects of a drug in a clinically important manner.
Pharmacogenomic advances have the potential to
improve the effectiveness and safety of oral antidiabetic therapy37,38 but have not yet reached the
stage of wide clinical applicability. This is in contrast
to the field of antithrombotic therapy where variants
in the CYP2C19 enzyme, which affect hepatic
activation of the widely used anti-platelet agent
clopidogrel, may result in clinically relevant reduction in drug effectiveness. Genetic testing for this
variant is available, but its role in routine practice
remains controversial.39 In the case of metformin,
the most widely used drug for DM2, recent findings
of the role of organic cationic transporter proteins in
the mechanism of action of metformin led to the
discovery that variants related to the genes for these
transporter proteins may reduce metformin
effectiveness40 and tolerance.41 A GWAS of DM2
patients linked responsiveness to metformin to a
SNP associated with the gene for ATM (ataxia
telangiectasia mutated).42 Although this genetic
variant accounts for only 2.5% of the variation in
metformin response, findings such as these facilitate
understanding of drug mechanisms of action.
Nutrigenetics and nutrigenomics
Nutrigenetics has been defined as the science of the
effect of genetic variation on dietary response, while
nutrigenomics studies the impact of nutrients and
other elements of the diet on gene expression.43
These new fields recognize the major interactions
between genetic make-up and response to diet and
dietary changes, both in terms of predisposing to
development of obesity, metabolic syndrome, and
DM2, and in determining responsiveness to specific
dietary changes. For example, while TCF7L2

4

January 2014  Volume 5  Issue 1  e0002

Personalized Medicine in Diabetes
(transcription factor 7–like 2 protein, which is
involved in the synthesis, processing, and secretion
of insulin) is strongly and consistently related to
DM2 risk, this risk is modulated by dietary carbohydrate and is greater when the diet contains larger
amounts of high glycemic-index foods.44
PERSONALIZED MEDICINE AND
PREDICTION OF DM2 RISK
The disordered metabolic state of type 2 DM is
characterized by elevated levels of glucose, resulting
from reduced effectiveness of insulin’s actions on its
target tissues with an inadequate compensatory
response of the insulin-secreting pancreatic islet βcells.45 The precise glucose levels at which DM2 is
diagnosed are necessarily arbitrary (based mainly on
the threshold for presence of background retinopathy in epidemiological studies),23 such that many
people who do not meet formal diagnostic criteria
for DM2 nevertheless have abnormally elevated
levels of glucose, along with a degree of insulin
resistance and inadequate insulin secretion. Such
individuals may already have evidence for diabetic
complications and are at risk for progression of
these abnormalities over time. A number of highquality randomized controlled trials have demonstrated that risk of progression to DM can be cut in
half,46 making it a priority to identify those at
greatest risk who are candidates for primary prevention measures.47
Based on current American Diabetes Association
recommendations,23 increased risk for DM2 (often
termed “prediabetes”), may be identified in one of
three ways: 1) fasting plasma glucose (FPG) of 100–
125 mg/dL (characterized as impaired fasting
glucose); 2) plasma glucose 2 hours after a 75-g oral
glucose challenge of 140–199 mg/dL (impaired
glucose tolerance); or 3) hemoglobin A1c (HbA1c)
test of 5.7%–6.4%. These criteria do not identify
identical groups of people at increased risk for DM2,
and their pathophysiology and susceptibility to
complications may differ. For example, those with
impaired glucose tolerance are at greater risk for
macrovascular complications, including stroke, than
those with impaired fasting glucose.48,49
While the prevalence of prediabetes is now as
high as 35% of US adults (50% of those 65 and
older), only a small number of these (as few as 3%)
develop DM2 each year.50 Even with the categorical
diagnosis of prediabetes, an individual’s risk for
progression to DM2 over 5 years can vary widely,
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from 100% (for those with HbA1c 6.0%–6.4% and
FPG 116–125 mg/dL) to close to zero (for those with
HbA1c < 6% and FPG < 110 mg/dL), based on
prospective studies in a Japanese population.51 Thus
a more precise personalized estimate of absolute
risk for developing DM2 than is provided for by the
broad categories of impaired fasting glucose, impaired glucose tolerance, and prediabetes is highly
desirable.
Personalized medicine has the potential to
improve prediction of DM2 risk. Simple clinical risk
factors (age, weight, family history of DM) and
simple laboratory measures (glucose, triglyceride)
explain about 80% of the variance in DM incidence.52 Novel clinical/anthropometric risk factors
for DM development continue to be reported.53 To
date at least 65 genetic variants contributing to DM2
have been identified,18,22 but these account for less
than 10% of cases. Initial studies with a limited
number of DNA markers showed only modest
incremental value of adding genetic data to clinical
information in predicting risk for DM2, 21,54,55 thus
the potential for genomics to enhance prediction of
DM2 risk remains unrealized.
While weight or body mass index (BMI) is
consistently a strong determinant of metabolic
syndrome and DM2, individuals with the same
weight or BMI may have very different risks of DM2.
A personalized assessment of the metabolic impact
of obesity needs to take into account the distribution
pattern of the excessive adipose tissue. Intraabdominal visceral and in particular hepatic fat
accumulation is associated with insulin resistance
and systemic inflammation, with increased risk for
metabolic syndrome, DM2, and cardiovascular
disease, while excess subcutaneous fat does not
impair insulin sensitivity, leading to the concept of
metabolically “benign versus malign” obesity.56
A large number of additional novel risk factors
(including FEV1, adiponectin, leptin, gamma-glutamyltransferase, ferritin, inter-cellular adhesion
molecule 1, complement C3, white blood cell count,
albumin, activated partial thromboplastin time,
coagulation factor VIII, magnesium, hip circumference, and heart rate) are each independently
associated with risk for DM2 but add little or
nothing to basic clinical prediction models in
predicting incident DM2.57 Sex hormone-binding
globulin (SHBG), traditionally considered to be a
passive transporter protein for sex steroids, may
have a more active role in DM causation. Observa-
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tional studies identified lower levels of SHBG as a
risk factor for insulin resistance and incident DM,
and in-vitro studies demonstrated G-protein-linked
receptor-mediated effects of SHBG on intracellular
processes related to insulin resistance.58 Multiple
confounding factors (e.g. obesity, hyperinsulinemia)
are associated with lower SHBG and risk for DM2;
however, recent genetic studies suggest an
independent role for sex steroids and SHBG in the
etiology of DM2.59
In recent years, metabolomic studies of large
numbers of metabolites in blood and/or urine have
identified novel predictors of DM risk, e.g. circulating levels of aromatic and branch-chained amino
acids, which are independent predictors of insulin
resistance60 and DM risk. Metabolomic studies have
identified novel pathophysiological mediators of
metabolic syndrome, such as nicotinuric acid.61
Using a targeted metabolomic approach and
measuring over 160 serum metabolites with flow
injection analysis tandem mass spectrometry in
prospectively collected samples from large
population-based studies, Floegel et al. identified a
number of changes in sugar metabolites, amino
acids, and choline-containing phospholipids that
modestly improve prediction of DM risk.62
Identifying such metabolomic markers may prove to
be useful in directing studies of the associated genes
in at-risk populations.63
PREDICTING TYPE 1 DM RISK
Autoimmune-mediated destruction of the insulin
producing β-cells of the pancreatic islets results in
type 1 DM. Increased risk for developing type 1 DM
may be recognized by a family history of type 1 DM
or other autoimmune diseases, by the presence in
the blood of a range of antibodies to insulin and
islet-related antigens (e.g. islet-cell antibodies,
insulin autoantibodies, antibodies to glutamic acid
decarboxylase), or by the identification of a “highrisk” HLA type.64 Recently genomic studies combined with bioinformatics techniques have been able
to identify a small number of SNPs that can rapidly
and inexpensively predict the presence of the highrisk HLA-DR/DQ types,64 which may facilitate
identification of those individuals who are candidates for studies of interventions to prevent
complete β-cell loss and thereby prevent or
ameliorate the type 1 DM.65
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PERSONALIZED MEDICINE AND
CHRONIC MICROVASCULAR
COMPLICATIONS OF DM
As a function of time and extent of hyperglycemic
burden, individuals with DM are prone to develop
renal, retinal, or neurological damage that can result
in renal failure, blindness, disabling pain, or lowerextremity amputations. However, not all patients
with DM develop these complications, regardless of
duration or degree of hyperglycemic control. Fifteen
to twenty years after diagnosis of DM, 50%–80%
have evidence for retinopathy,66 only a minority of
which is vision-threatening, up to 30% have
increased levels of albumin in the urine (an early
stage in the development of nephropathy),67 and
about 50% have symptoms of peripheral
neuropathy.68 Randomized controlled trials, including DCCT,69 UPKDS,70 Kumamoto,71 ACCORD,72 and
ADVANCE,73 demonstrate the potential to reduce or
delay some or all of these risks by controlling
hyperglycemia. It has also become apparent that
uncontrolled hyperglycemia early in the course of
DM may result in sustained increased risk of
complication development, regardless of subsequent
glycemic control. This concept of “metabolic
memory” may reflect epigenetic changes (e.g. DNA
methylation and post-translational histone modification).74 Personalized management of complication
risk would be greatly enhanced by improved
discrimination of those not destined to develop the
complication from those who would most benefit
from aggressive measures to reduce their risk.
Diabetic Nephropathy Prediction and
Prevention
Nephropathy occurring as a complication of type 1
and type 2 DM is characterized clinically by
increased levels of protein in the urine, declining
glomerular filtration rate, hypertension, and
eventual progression to renal failure, requiring renal
replacement therapy with dialysis or transplantation. Not all patients with DM develop albuminuria,
and this is not always progressive. Progression may
be slowed by excellent glycemic and blood pressure
control, as well as use of angiotensin-converting
enzyme inhibitor medications.75
Numerous clinical factors are associated with
risk for nephropathy (blood pressure, age, obesity,
extent of hyperglycemia). There is also a clear
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inherited (familial and racial) contribution to
nephropathy susceptibility. Although genome-wide
association studies have not identified definite DM
nephropathy susceptibility loci in DM2, ongoing
family studies may provide clues to uncommon gene
variants that increase nephropathy risk.76 Studies to
date have also not clearly confirmed a specific gene
marker associated with nephropathy in type 1 DM.77
Transcriptomic studies of non-coding RNA
molecules involved in regulation of gene expression
point to their role in influencing renal response to
hyperglycemia,78 and measurement of specific
microRNAs in the urine may improve prediction of
risk for development and progression of DM
nephropathy.78 New proteomic techniques may
permit earlier recognition, and therefore more
directed treatment, of those at risk for DM
nephropathy.79 One such novel urinary marker is
liver-type fatty acid-binding protein, which may
enhance prediction of risk for progression of early
nephropathy in type 1 DM.80 The ability to identify
diabetic patients not at risk for future nephropathy
would permit relaxed screening and treatment
recommendations.
Diabetic Retinopathy Prediction and
Prevention
Eye changes in DM result from abnormal retinal
microvasculature (microaneurysms with abnormal
permeability as well as vascular occlusion with
consequent ischemia and neovascularization).81
Background retinopathy changes may be evident at
the time of diagnosis of DM2 and eventually develop
in the majority of type 1 and type 2 DM patients.
Only a minority of these progress to visionthreatening proliferative retinopathy, typically as a
function of time and degree of glycemic control,
especially in the presence of other complications like
nephropathy or non-healing foot ulcers.82 Medical
interventions are effective in arresting the progresssion of vision-threatening retinopathy, forming the
basis of current screening recommendations for
asymptomatic retinopathy in all type 1 and type 2
DM.4–6 Along with improved glycemic control in
recent decades, this has led to a declining incidence
and severity of diabetic retinopathy in the USA.83 In
recent years genomic studies have identified
potential genetic associations with DM retinopathy
risk, for example the gene encoding the receptor for
advanced glycation end products (RAGE, especially
the 1704T allele)84 and the gene for methylenetetrahydrofolate reductase (MTHFR),85 where the
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677C/T polymorphism has been associated with
modestly increased risks for nephropathy and
retinopathy. Investigators have recently reported
use of proteomic methods to study proteins in the
aqueous humor of the eye that may provide insights
into the pathophysiology of DR,86 but proteomic and
genomic testing for diabetic retinopathy risk are not
yet useful in clinical practice.
Diabetic Neuropathy Prediction and
Prevention
Peripheral nerve dysfunction results from metabolic
as well as microvascular damage and may lead to
significant pain, as well as loss of sensation
predisposing to lower-extremity amputation.
Autonomic neuropathies affect gastrointestinal
motility and can lead to cardiac dysfunction. Risk
for neuropathy rises with duration of DM, degree of
hypertension and hyperglycemia, as well as
smoking.87 Vitamin D insufficiency may also be an
independent predictor of developing neuropathy
symptoms.68 Nevertheless, about 50% of DM
patients appear resistant to these factors and do not
develop neuropathy. Recent proteomic studies of
patients with diabetic neuropathy have identified a
number of proteins, including a fragment of the
apolipoprotein C-I precursor, that associate with
diabetic neuropathy.88 Metabolomic studies have
identified phospholipid biomarkers that may
improve discrimination between those DM patients
with and without neuropathy.89 Such advances may
lead to improved assessment of neuropathy risk and
may enhance understanding of the pathophysiology
of diabetic neuropathy.
PERSONALIZED MEDICINE AND
CHRONIC MACROVASCULAR
COMPLICATIONS OF DM
While historically much attention was focused on
preventing the aforementioned microvascular
complications of DM, in reality the most significant
area of preventable DM-related morbidity, mortality, and heath care utilization90 is arteriosclerotic
narrowing in the coronary, cerebrovascular, and
peripheral arterial beds. This results in the
devastating manifestations of angina pectoris, acute
myocardial infarction, sudden cardiac death, heart
failure, stroke, intermittent claudication, and lowerextremity amputation. Risk of atherosclerotic
cardiovascular disease (ASCVD) rises with fasting
glucose even in the “prediabetes” range.91 While
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glycemic control in the short or medium term
appears to have little impact on the course of these
macrovascular manifestations, long-term follow-up
studies from the DCCT92 and the UKPDS70 trials
(including type 1 and type 2 DM patients,
respectively) showed a beneficial long-term “legacy”
effect of early glycemic control on long-term
macrovascular disease risk. In contrast to glycemic
control, there is strong evidence that addressing
other cardiac risk factors (encouraging smoking
cessation, use of angiotensin-converting enzyme
inhibitor drugs, control of blood pressure and
elevated LDL-cholesterol, as well as use of antiplatelet agents) substantially lowers short- and longterm risk of macrovascular events in those with
DM2.93 A clinically important barrier to therapy
with HMG-CoA reductase inhibitors (“statins”) in
DM is the occurrence of muscular symptoms, which
typically are mild (aching, weakness) but rarely may
be severe or life-threatening (rhabdomyolysis).
Recent pharmacogenetic studies found that variants
in the SLCO1B1 gene (affecting cytochromemediated drug clearance) are associated with an
increased risk of statin-induced myopathy,94
particularly with simvastatin but not pravastatin.
In some studies, those with DM2 but without
history of cardiac events bear the same risk of
experiencing a cardiac event as non-DM patients
who have already experienced an event.95 As a
result, primary prevention of ASCVD in DM2 is
treated in the same way as secondary prevention in
those without DM (“DM as a coronary disease
equivalent”).4 Consequently, patients with DM2
typically are exposed to the costs, complexity, and
risk of side effects from poly-pharmacy, receiving
multiple medications to lower LDL-cholesterol and
blood pressure as well as glucose. Improved assessment of ASCVD risk would allow for a more personalized implementation of these preventive measures.
More than a dozen models have been developed to
predict absolute risk for ASCVD in DM2 patients,
which vary in their predictive power (AUC ranging
from 0.61 to 0.86), validation, and evidence for
impact on clinical practice and outcomes.96
Estimates of ASCVD risk need to take into account
ethnicity.97 All use clinical variables (such as age,
gender, HbA1c, duration of DM, presence of
albuminuria, tobacco use, measures of blood
pressure, and lipid parameters). None incorporate
novel risk factors such as soluble receptors for
advanced glycation end products (sRAGE),98 hsCRP
or other measures of inflammation, markers of
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endothelial dysfunction, or growth factors such as
placental growth factor or transforming growth
factor-β that are associated with increased cardiac
risk.99 None to date include genomic, proteomic, or
metabolomic information.
A novel predictor of ASCVD risk in those with
both type 1 and type 2 DM is the haptoglobin
genotype.100 Haptoglobin is a circulating hemoglobin-scavenging protein that exists in three
variants: 1-1, 1-2, and 2-2. A number of studies
identified a doubled risk for ASCVD for those with
the 2-2 genotype,100 which is present in approximately 36% of DM2. An intriguing pharmacogenomic finding from intervention trials is that only
those DM patients with the 2-2 genotype appear to
respond to anti-oxidant treatment (vitamin E) with
reduced ASCVD risk of up to 50%.100 If these
findings are confirmed, then testing for haptoglobin
genotype of all DM patients could be recommended,
with addition of vitamin E treatment to reduce
ASCVD risk for those with the 2-2 genotype.
Genomic approaches (GWAS) not specifically in
patients with DM have identified more than 20
variants (SNPs) that are associated with increased
risk for coronary artery disease.101 In patients with
DM2, a genetic predisposition score derived from
GWAS of DM2 predisposition was independently
associated with risk for cardiovascular complications,102 pointing to an overlapping etiological basis
for DM2 and ASCVD. However, it is not clear that
genomic information enhances the more traditional
clinical risk factor approach to ASCVD prediction.103
Nevertheless, genomic studies of coronary artery
disease, as with DM2 itself, have potential to
improve understanding of pathophysiology, predicttion, prognosis, diagnosis, and management.104
Studies of circulating microRNA in patients with
DM found that presence of peripheral vascular
complications in DM is associated with loss of
endothelial mIR-126, possibly due to disturbed
fibrinolysis.26 This field of study has potential to
increase understanding of the pathophysiology of
diabetic macrovasculopathy. Proteomic studies of
vascular tissue, plaque, and body fluids from
patients with atherosclerosis have been performed,
with some progress in identifying potential
biomarkers of disease activity or disease risk, as well
as proteins of potential pathophysiological significance. Proteomic approaches have identified
unusual apolipoprotein patterns in the small dense
LDL of insulin-resistant patients with DM and
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metabolic syndrome that may help explain their
susceptibility to ASCVD.105
PERSONALIZED MEDICINE AND DM
TREATMENT
A goal as yet unrealized in the clinical management
of patients with DM is to use genomic, metabolic,
and other data to predict which patients will
progress to a particular complication of DM, in
order to establish an indication for specific preventive interventions. Within the realm of preventive
therapy, the ideal situation would be the ability to
predict individual responsiveness to and tolerance of
a particular treatment, in order to design the most
effective and best-tolerated individual program of
drug, dietary, and exercise therapies. There has been
modest progress in understanding the pharmacogenomics of the glucose-lowering medications,37 but
practical implementation remains elusive. Thus,
choice amongst drugs and drug classes for DM
remains largely empirical.8
Compared to the field of pharmacogenomics
there has been less research into the genetic
determinants of responsiveness to dietary change or
increased physical activity, two key modalities in the
prevention and treatment of DM. Intriguing recent
studies point to differential sensitivity to particular
dietary regimens based on genotype. Genome-wide
association studies have identified a number of
genetic loci that associate with BMI,106 one of the
most consistent of which is the “fat mass and obesity
associated gene” (FTO). Interaction between FTO
variants and diet and exercise has been found. The
interaction between FTO and risk of obesity is
modulated by exercise, in that increased levels of
physical activity attenuate the rise in weight seen in
men carrying the FTO rs1861868 SNP.107 Interaction
with diet has also been found, with recent
randomized trial data suggesting that individuals
with the FTO variant rs1558902 showed enhanced
changes in weight, body composition, and
superficial fat mass in response to a high-protein
diet,108 while subjects with the TCF7L2 rs12255372
genotype showed greater reduction in weight and
DM risk by consumption of a low fat (20%) diet.109 If
these kinds of findings are confirmed, specific
dietary prescription for patients with obesity and
DM2 may be aided by genomic testing. However, it
is not clear that information about genetic risk
influences behavior in a clinically useful manner. A
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recent randomized control trial found no significant
effect of counseling on personalized genetic risk for
DM2 on participation in and outcome of a lifestyle
change program to prevent DM2.110
A recent GWAS linked genetic variants in the
SGIP1, CYP19A1, and LEPR genes to voluntary
leisure-time activity, independently of BMI. Even
though these effects were small, studies such as this
point to possible explanations for variations in
habitual exercise activity and related health consequences.111 Great variation in individual responses to
exercise training has long been recognized, both in
terms of improved muscle strength and aerobic
performance. Genetic determinants underlying this
variation have been uncovered. Variants in the
ISIG2 gene (a gene associated with obesity) contribute to variation in subcutaneous fat in women and to
attenuation of the effects of resistance training in
men.112 Variants in the genes for CCL2 (chemokine
(C-C motif) ligand 2) and its receptor (CCR2), a
chemokine related to muscle repair and response to
exercise, influence muscle strength and response to
strength training.113 In spite of these preliminary
findings, “exercise prescription” for patients with
DM remains largely empirical, and clearly much
research remains to be done in order to understand
adequately the individual variation in response to
physical training,114 and in order to match optimally
the exercise recommendations to individual patients
with DM.
ECO-SYSTEM IN PERSONALIZED
MEDICINE
Improved diet and exercise are hallmarks of DM
prevention and treatment. However, they are
difficult to sustain. When prescribing such treatments, the caregiver has to be aware of the patient’s
eco-system at the point of care. For example, a
project involving a US Veterans Administration’s
data set has been recently launched in order to apply
personalized medicine at the point of care. This data
set contains 10 million patient records with demographic, clinical, and genomic data. The demographic data will be analyzed and processed to
render approximate geolocation. A high-performance query interface will be enabled to co-query
records based on geography, clinical, and genomic
attributes. Interactive data maps and heat maps will
be created. The data set will be mined for the
derivation of knowledge, and, utilizing The Terra Fly
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Geospatial Analytics System (http://terrafly.com),
correlates of eco-system components with DM and
obesity will be determined. For example, studies
have indicated that residents of neighborhoods
without sidewalks tend to be overweight.115 The
absence of sidewalks seems to be a factor in
discouraging people from walking, thus reducing the
potential benefits of this simple exercise to prevent
and treat DM. The presence of sidewalks is
automatically derivable from analysis of aerial and
satellite images and property boundaries represented by polygons; it allows correlation of findings from
imagery analysis and the obesity demographics
statistics.
PERSONALIZED MEDICINE AND DM
TREATMENT TARGETS
Recent guidelines recommend moving away from
uniform glycemic control goals for people with
DM,4,8 with the result that the majority of DM
patients may not be candidates for the most
aggressive HbA1c goals.116 Personalization of
glycemic control target is based on clinical
parameters, including age, duration of DM, and
presence of DM complications or co-morbidities,
and eco-system components. If microvascular or
macrovascular risk could be more precisely assessed
than currently, more or less aggressive treatment
targets could be used, not just for glucose, but also
for blood pressure and lipid lowering treatments.

CONCLUSIONS
Patients, physicians, health care organizations, and
policy planners are grappling with the worldwide
rise in incidence of DM. Diabetes mellitus and its
related complications cause substantial morbidity
and mortality and are consuming an increasing
proportion of health care budgets. There is wide
individual and ethnic variation in susceptibility to
DM as well as environmental factors, making a “one
size fits all” approach to DM management inefficient. The vision of DM care in the era of personalized medicine is that patients and physicians, using
decision support systems embedded in the
electronic medical record at the point of care, will
have access to the results of individualized genomic,
proteomic, and metabolic information, as well as the
most current evidence-based guidelines and
literature updates.12 This will provide them with upto-date, accurate, and actionable information on risk
for DM and its diverse manifestations, allowing
them jointly to prioritize and optimize diagnostic,
treatment, and monitoring plans. In this way, the
most cost-effective and best-tolerated treatments
can be directed at the manifestations of disease most
likely to impact that individual’s health and life
expectancy, while avoiding treatments that are
unlikely to be of benefit. The tools of personalized
medicine have made substantial progress towards
understanding the pathophysiologic mechanisms
behind individual variation in DM and its
manifestations.

GLOSSARY
Term

Definition

Examples of Techniques Used

Personalized medicine

“The tailoring of medical treatment to
the individual characteristics of each
patient”10

Genomics

“The study of all of a person’s genes (the
genome), including interactions of those
genes with each other and with the
person’s environment”117

Genome-wide
association study
(GWAS)

“An approach used in genetics research to
look for associations between many
(typically hundreds of thousands) specific
genetic variations (most commonly singlenucleotide polymorphisms) and particular
diseases”118

Epigenetics

“Changes in gene expression and cellular
phenotypes that are mitotically stable but
that occur without accompanying changes
in primary DNA sequence”22
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Genome-wide association studies

Studies of gene methylation patterns
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Term

Definition

Examples of Techniques Used

Transcriptomics

“The quantitative study of all genes
expressed in a given biological state”25

Gene expression microarrays; RNA
sequencing25

Proteomics

Large-scale analysis of all the proteins in
an organism, tissue type, or cell (called
the proteome). Proteomics can be used to
reveal specific, abnormal proteins that
lead to diseases

Matrix-assisted laser
desorption/ionization28; mass
spectroscopy; electrospray ionization29

Metabolomics
(metabolic profiling)

“Measurements of the metabolome, which
represents the entire collection of all
small-molecule metabolites present in
any biological organism”36

Nuclear magnetic resonance; mass
spectrometry36

Pharmacogenomics

“Pharmacogenomics is the study of an
individual’s interaction with a specific
drug based upon the genetic make-up of
the individual”39

“Pharmacogenomics studies the
influence of genetic variations on the
patient’s response to specific drugs,
such as the correlation between the
efficacy or toxicity of a certain drug
and a specific gene expression or a
single-nucleotide polymorphism”39

Bioinformatics

“Information technology as applied to the
life sciences, especially the technology
used for the collection and analysis of
genomic data”118
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